Vertaling van "applications ●● further " (Nederlands → Frans) :

TERMINOLOGIE

extracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur extracorporel de système d’hyperthermie de circulation extravasculaire

handbediende applicator voor brachytherapiesysteem voor oog
applicateur manuel de système de brachythérapie oculaire

applicator voor thermisch pulsatiesysteem voor ooglid
applicateur pour système de traitement thermique par impulsions sur les paupières

applicator voor oesofageaal brachytherapiesysteem met op afstand bedienbare afterloading
applicateur de système de brachythérapie pour l’œsophage à chargement différé à distance

intracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur intracorporel de système d’hyperthermie de circulation extravasculaire

handbediende applicator voor oesofageaal brachytherapiesysteem
applicateur manuel de système de brachythérapie pour l’œsophage

applicator voor aneurysmaclip
applicateur de clips d’anévrisme

applicator voor compressiekousen
enfile-bas de contention

applicator voor tandheelkundige hars
applicateur de matériau de restauration dentaire

applicator voor dermale anesthesie
applicateur dermique d’anesthésie locale

IN-CONTEXT TRANSLATIONS

Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of
Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Our lost-time accident rate has declined by 75% since 1997 – thanks to the rigorous application of safety systems and procedures, combined with ongoing employee training – and we are determined to reduce it further.
Depuis 1997, notre taux d’accidents avec arrêt de travail a baissé de 75%, grâce à une application rigoureuse de nos mesures de sécurité, combinée à nos efforts permanents de formation des employés. A l’avenir, nous sommes déterminés à ce que ce taux diminue encore.